InnoVec Biotherapeutics Receives Second FDA IND Clearance for Ophthalmic AAV Gene Therapy IVB103, Now Targeting X-Linked Retinoschisis
Innovecbio
Gene Editing Delivery Technology and Drug Developer
Click on the image to register for free2025 IBI EXPO
December 10, 2024
eMedClub News
Recently, Innovecbio announced thatIVB103 InjectionReceived the FDA's IND approval in the United States,For treatmentX-linked retinoschisis (XLRS). Public information shows,IVB103 is a self-developed product by Innovecbio.AAV Gene Therapy Candidate for Intravitreal Administration。
Previously, in July this year, IVB103 received IND approval from the U.S. FDA for the treatment of neovascular age-related macular degeneration (nAMD);In October this year,IVB103 Receives Clinical Approval from China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the Treatment of nAMD.
2025 (3rd) Biologics Innovation Conference
Pre-registration Opened
Swipe up to view the schedule
IVB103 Injection is an innovative drug developed by Innovecbio using its self-developed EASI-AAV technology platform. By modifying and optimizing the vector, it improves its infection efficiency and targeting in the human body. This enables IVB103 to deliver therapeutic genes into retinal cells more effectively.Inhibition of neovascularization, thereby exerting a therapeutic effect.
AboutInnovecbio
InnoVec Biotherapeutics Inc. (Innovecbio) is a clinical-stage gene therapy company driven by vector innovation. The company is dedicated to developing gene therapy delivery tools suitable for human use, addressing the challenges in the translation of delivery tools from animals to humans during development.The goal is to find gene delivery tools for all tissues and organs, enabling gene therapy to be widely applied to both rare and common diseases.Innovecbio has efficient teams in technical development, pipeline research, process optimization, and clinical operations. It has established a leading technology development platform, covering multiple disease areas such as ophthalmology, neurology, and muscular diseases. Several innovative products have entered the IIT and IND stages.
Welcome everyone to register for the 2025 IBI EXPO conference and move forward with the times. Below is the 2024 IBI EXPO.Highlights of the live video.
Registration and Event Consultation
IBI EXPO 2025 (3rd) Biopharmaceutical Innovation ConferenceWill beMarch 1, 2025 to March 2, 2025InSuzhou International Expo CenterGrandly held. The theme of the conference isCollaboratively Build the Full Chain, Innovate and Transform the New Ecosystem。
The conference will invite300+Guest Speaker, Opening30+Field Forum Activities, Covering Hundreds of Hot Topics, AroundCell and Gene Therapy, Radiopharmaceuticals, Antibody Innovation Conjugation, Targeted Protein Degradation, Stem Cell Regeneration, mRNA Vaccines and Nucleic Acid Drugs, Exosomesetc.New Molecular Drugs,AI Drug Discovery, Organoids, Novel Delivery Vehiclesetc.Cutting-edge Technology，Engage in exchange and discussion, and collaborate.Pharmaceutical companies, research institutions, clinical resources, supply chain enterprises, investment and financing institutions, park governmentsBy leveraging multiple forces to drive the transformation of cutting-edge innovations from scientific research to industrial applications, a source of development is injected into the biopharmaceuticals market.
Free Participation:Teacher Yang 15517201185
Free Exhibition:Teacher Yuan 15572286596
Speech & Media：Teacher Wang 18717836231
Exciting Live Broadcast Preview
Long press to scan the QR code and participate immediately ↓
Recommendation 1
December 19th (Thursday) 19:00-20:00
Rapid Process Development for Cell Therapy
DianDian "Share”、“Like" and "In Progress", give me a little recharge~"